MedTrace Logo

Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment

NCT03926585 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2023-05-25

No results posted yet for this study

Summary

Hypothesis: Variations in the deiodinase 2 gene and monocarboxylate transporter 10 gene is associated with improvement in quality of life after initiation of combination therapy with L-Thyroxine and Liothyronine in patients with persistent hypothyroid symptoms despite conventional L-thyroxine mono-therapy.

Purpose: To re-test this hypothesis in patients with continued perceived effect of Liothyronine treatment at least one year after initiation in a patient population more representing of daily clinical practice. The study will help determine whether testing of specific gene variations might predict longtime effect of combination therapy.

Conditions

Sponsors & Collaborators

  • Birte Nygaard

    lead OTHER

Principal Investigators

  • Birte Nygaard, Ph.D. · Herlev Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03926585 on ClinicalTrials.gov